Congratulations to our portfolio company Thryv Therapeutics Inc. on their announcement today of positive top-line results from their Wave I Part 2 study in Long QT Syndrome Type 2 & 3 patients. See below for more information #Biotech #VentureCapital #Healthcare #LQTSyndrome #AmplitudeVC
Breakthrough Update! 🚀 We’re thrilled to share positive top-line results from our Wave I Part 2 study in Long QT Syndrome Type 2 & 3 patients. This brings us one step closer to improving lives. Read the full press release here: https://loom.ly/RySKvWc 💚 #LQTS #ClinicalResearch #LongQTSyndrome #WaveStudies #BeRelentless